Tempus AI (NASDAQ:TEM) shares are up on Tuesday as the company announced the acceptance of 31 abstracts for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026.

The ACCR meeting is taking place on April 17–22.

Tempus’ abstracts include a series of studies highlighting emerging biomarkers, molecular subtypes, and real-world evidence aimed at refining cancer treatment strategies across multiple tumor types.

On Monday, Jefferies initiated coverage on Tempus AI with an Underperform rating and a price forecast of $35.

MSI And Gene Fusions Define Distinct CRC Subtype

One study examining over 30 million colorectal cancer cases found that gene fusions are significantly more common in tumors with microsatellite instability (MSI) compared to microsatellite stable (MSS) tumors.

The enrichment—6.2% versus ...